Actively Recruiting
Combined Personalized Neoantigen-loaded Dendritic Cell Vaccine, PD-1 Inhibitor, and Radiotherapy for Adults with Advanced Non-Small Cell Lung Cancer After Second-Line Treatment
Led by The First Affiliated Hospital of Nanchang University · Updated on 2024-12-30
10
Participants Needed
2
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combined treatment for patients with advanced non-small cell lung cancer NSCLC that has worsened after second-line therapy. The study aims to assess the effectiveness and safety of using a personalized tumor neoantigen-loaded dendritic cell DC vaccine together with a PD-1 inhibitor and radiotherapy. This phase 2 study involves 10 patients and follows strict ethical guidelines. The treatment includes a personalized course of radiotherapy followed by PD-1 inhibitor infusions every three weeks. Alongside this, patients receive 10 subcutaneous injections of the personalized neoantigen-loaded DC vaccine over 21 weeks. The vaccine administration is divided into a primary phase with six treatments and a boost phase with four treatments, scheduled at specific intervals. Radiotherapy details and dosage are tailored by the patients physician. Participants will undergo regular follow-up visits every six weeks after treatment until the study ends. At each visit, they will have blood samples taken, physical exams, performance status assessments, imaging scans such as CT or MRI, X-rays, and laboratory tests. Researchers will monitor outcomes including objective response rate, disease control rate, safety measures, progression-free survival, and overall survival throughout an average study duration of 32 weeks or longer as applicable.
CONDITIONS
Brief Title
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
Research Team
Y
Yong Li, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here